U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C34H44N4O4
Molecular Weight 572.7376
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAZEMETOSTAT

SMILES

CCN(C1CCOCC1)C2=C(C)C(=CC(=C2)C3=CC=C(CN4CCOCC4)C=C3)C(=O)NCC5=C(C)C=C(C)NC5=O

InChI

InChIKey=NSQSAUGJQHDYNO-UHFFFAOYSA-N
InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)

HIDE SMILES / InChI

Description

Tazemetostat (EPZ-6438) is a selective inhibitor of histone-lysine N-methyltransferase EZH2. The drug is under clinical development (phase II) for the treatment of Diffuse Large B Cell Lymphoma, Malignant Mesothelioma and Synovial Sarcoma.

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.
2013 May 7
Patents

Sample Use Guides

In Vivo Use Guide
Malignant Mesothelioma, Synovial Sarcoma: patients receive 800 mg of oral tazemetostat two times daily. Diffuse Large B Cell Lymphoma: patients receive 200, 400, 600 or 800 mg of the drug twice a day in combination with rituximab (IV, 375 mg/m2, day 1),pPrednisolone (PO, 40 mg/m2 in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m2, day 1), cyclophosphamide (IV, 750 mg/m2, day 1), vincristine (IV, 1.4 mg/m2, day 1): 8 cycles, every 21 days.
Route of Administration: Oral
In Vitro Use Guide
Treatment of WSU-DLCL2 with 1uM tazemetostat for 4 days resulted in a concentration-dependent reduction in global H3K27Me3 levels with an IC50 value of 9 nmol/L. Treatment of WSU-DLCL2 cells with 200 nM tazemetostat; KARPAS-422 with 100 nM; SU-DHL-6 with 200 nM; and Pfeiffer with 0.5 nM inhibited cell proliferation with IC50 values of 0.0086, 0.0018, 0.0047 and 0.00049 uM, respectively.
Name Type Language
TAZEMETOSTAT
WHO-DD  
USAN   INN  
Official Name English
TAZEMETOSTAT [USAN]
Common Name English
E-7438
Code English
EPZ-6438
Code English
TAZEMETOSTAT [INN]
Common Name English
TAZEMETOSTAT [WHO-DD]
Common Name English
N-((4,6-DIMETHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)-5-(ETHYL(OXAN-4-YL)AMINO)-4-METHYL-4'-((MORPHOLIN-4-YL)METHYL)(1,1'-BIPHENYL)-3-CARBOXAMIDE
Systematic Name English
E7438
Code English
(1,1'-BIPHENYL)-3-CARBOXAMIDE, N-((1,2-DIHYDRO-4,6-DIMETHYL-2-OXO-3-PYRIDINYL)METHYL)-5-(ETHYL(TETRAHYDRO-2H-PYRAN-4-YL)AMINO)-4-METHYL-4'-(4-MORPHOLINYLMETHYL)-
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 637118
Created by admin on Mon Oct 21 20:48:21 UTC 2019 , Edited by admin on Mon Oct 21 20:48:21 UTC 2019
FDA ORPHAN DRUG 508415
Created by admin on Mon Oct 21 20:48:21 UTC 2019 , Edited by admin on Mon Oct 21 20:48:21 UTC 2019
NCI_THESAURUS C274
Created by admin on Mon Oct 21 20:48:21 UTC 2019 , Edited by admin on Mon Oct 21 20:48:21 UTC 2019
EU-Orphan Drug EU/3/18/2004
Created by admin on Mon Oct 21 20:48:21 UTC 2019 , Edited by admin on Mon Oct 21 20:48:21 UTC 2019
FDA ORPHAN DRUG 544416
Created by admin on Mon Oct 21 20:48:21 UTC 2019 , Edited by admin on Mon Oct 21 20:48:21 UTC 2019
FDA ORPHAN DRUG 578417
Created by admin on Mon Oct 21 20:48:21 UTC 2019 , Edited by admin on Mon Oct 21 20:48:21 UTC 2019
FDA ORPHAN DRUG 607017
Created by admin on Mon Oct 21 20:48:21 UTC 2019 , Edited by admin on Mon Oct 21 20:48:21 UTC 2019
Code System Code Type Description
EVMPD
SUB178719
Created by admin on Mon Oct 21 20:48:21 UTC 2019 , Edited by admin on Mon Oct 21 20:48:21 UTC 2019
PRIMARY
PUBCHEM
66558664
Created by admin on Mon Oct 21 20:48:21 UTC 2019 , Edited by admin on Mon Oct 21 20:48:21 UTC 2019
PRIMARY
CAS
1403254-99-8
Created by admin on Mon Oct 21 20:48:21 UTC 2019 , Edited by admin on Mon Oct 21 20:48:21 UTC 2019
PRIMARY
INN
9963
Created by admin on Mon Oct 21 20:48:21 UTC 2019 , Edited by admin on Mon Oct 21 20:48:21 UTC 2019
PRIMARY
NCI_THESAURUS
C107506
Created by admin on Mon Oct 21 20:48:21 UTC 2019 , Edited by admin on Mon Oct 21 20:48:21 UTC 2019
PRIMARY